When is it appropriate to increase the dose of Invega Sustenna (paliperidone palmitate) and what is the recommended dosing schedule?

When to Increase Invega Sustenna Dose

Increase the monthly maintenance dose of Invega Sustenna when there is inadequate symptom control after at least 14-21 days following initial titration, adjusting within the available dose range (39-234 mg) based on tolerability and efficacy, with a maximum monthly dose of 156 mg for patients with mild renal impairment. 1

Dosing Framework

Standard Maintenance Dosing

• Recommended monthly maintenance dose: 117 mg (75 mg eq. paliperidone)
• Available dose range: 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg
• Adjustment basis: Previous clinical history of tolerability and/or efficacy 1

Timing of Dose Increases

The FDA labeling explicitly states that dose adjustments should occur at widely spaced intervals after initial titration 2. This aligns with early psychosis guidelines recommending dose increases only after 14-21 days if response has been inadequate 2.

Key principle: Do not rush dose escalation. The pharmacokinetic profile of paliperidone palmitate shows that steady-state concentrations are achieved gradually, with maximum plasma concentrations reached at approximately 13 days post-injection 3. Clinical response may lag behind plasma levels.

Clinical Indicators for Dose Increase

Increase the dose when:

• Persistent positive symptoms (hallucinations, delusions) remain inadequately controlled after 2-3 weeks at current dose
• Functional impairment continues despite initial treatment period
• No limiting side effects are present (particularly extrapyramidal symptoms or excessive sedation)

Dose Escalation Strategy

1. Start at 117 mg monthly (standard maintenance dose) 1
2. Wait minimum 14-21 days to assess response 2
3. Increase incrementally to next available strength (156 mg, then 234 mg if needed)
4. Monitor for tolerability at each dose level, particularly extrapyramidal symptoms 2

Special Population Considerations

Mild renal impairment (CrCl 50-80 mL/min):

• Start with 78 mg monthly maintenance
• Maximum dose: 156 mg (do not exceed this in renal impairment) 1

First-episode psychosis patients:

• Use lower end of dosing range initially
• The guideline emphasizes avoiding extrapyramidal side effects to encourage future adherence 2
• Maximum equivalent of 4-6 mg haloperidol or 4 mg risperidone/20 mg olanzapine in first-episode patients 2

Critical Pitfalls to Avoid

1. Premature dose escalation: Waiting less than 14 days between increases risks accumulation and side effects without allowing adequate time to assess efficacy 2

2. Ignoring extrapyramidal symptoms: These should be avoided as they significantly impact adherence 2. If present, do not increase dose.

3. Exceeding maximum doses in renal impairment: The 156 mg ceiling in mild renal impairment is absolute 1

4. Flexible dosing window: Monthly doses can be given ±7 days without clinically significant impact on plasma concentrations 4, 5, but this flexibility should not be confused with the need for adequate assessment intervals between dose increases

Pharmacokinetic Rationale

Research demonstrates that paliperidone palmitate exhibits dose-proportional exposure increases within each dosing schedule 4, 6. The onset of efficacy begins as early as Day 8 after the initial 234 mg loading dose 7, but full therapeutic effect requires time. Population pharmacokinetic modeling supports the monthly dosing interval and confirms that plasma concentrations stabilize over multiple injections 4, 6.

The extended-release characteristics mean that dose adjustments have delayed and prolonged effects—another reason to space increases appropriately 1.